Beacon Behavioral Partners Expands to Pennsylvania with Partnership of Nexus Group
15 août 2024 15h17 HE
|
Beacon Behavioral Partners
Beacon Behavioral Partners announces its first partnership in Pennsylvania with Pittsburgh-based outpatient mental health facility Nexus Group.
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
09 août 2024 18h28 HE
|
Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
24 juil. 2024 10h00 HE
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Today's Webinar from the Brain & Behavior Research Foundation - Motivational Modulation of Cognitive Control in ADHD
09 juil. 2024 09h41 HE
|
Brain & Behavior Research Foundation
New York, July 09, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Motivational Modulation of Cognitive Control in ADHD” today, July 9, 2024,...
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
09 juil. 2024 07h00 HE
|
STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems
01 juil. 2024 04h30 HE
|
Nexstim Oyj
Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
27 juin 2024 07h10 HE
|
STALICLA
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...
Global Mental Health Screening Market Size To Worth USD 2.62 Billion By 2033 l CAGR of 11.78%
18 juin 2024 16h00 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , June 18, 2024 (GLOBE NEWSWIRE) -- The Global Mental Health Screening Market Size is to Grow from USD 0.86 Billion in 2023 to USD 2.62 Billion by 2033, at a Compound Annual...
Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path to More Personalized Treatments - A Free Webinar from the Brain & Behavior Research Foundation
03 juin 2024 13h19 HE
|
Brain & Behavior Research Foundation
New York, June 03, 2024 (GLOBE NEWSWIRE) -- NEW YORK -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path...
Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder - A Free Webinar from the Brain & Behavior Research Foundation
07 mai 2024 11h13 HE
|
Brain & Behavior Research Foundation
New York, May 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder” on...